Published in Biotech Business Week, December 25th, 2006
Roche made this decision subsequent to a periodic internal review of its development programs. This decision follows another decision by Roche earlier this year to discontinue its involvement in the co-development of daclizumab for the treatment of asthma. The codevelopment agreement between PDL and Roche will formally terminate in May 2007.
As a result, PDL will hold exclusive development and commercial rights to daclizumab for transplant maintenance, which...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.